HURA
TuHURA Biosciences, Inc.·Healthcare
2.27
15.816%(+0.31)
Market ClosedLast Updated: — ET
52W L: $0.4152W H: $4.44
HURA NEWS
prnewswire.com
3d ago
TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations
Mrs. Garofalo brings over 20 years of experience in Phase I-IV drug and biologic development TAMPA, Fla., April 7, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced Amanda Garofalo, MSHS, as Senior Vice President (SVP) of Clinical Operations.
prnewswire.com
Apr 1
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
TAMPA, Fla., April 1, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's fourth quarter and full year ended December 31, 2025, and provided a corporate update.
feeds.newsfilecorp.com
Mar 24
Advancements in Novel Immunotherapeutics in The Oncology Battle
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - March 24, 2026) - Investorideas.com, a go-to investing platform, releases an industry
prnewswire.com
Mar 23
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than $16 billion in worldwide sales TAMPA, Fla., March 23, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced Dr. Craig L.
defenseworld.net
Mar 14
TuHURA Biosciences (NASDAQ:HURA) Trading Down 3.1% – Here’s Why
TuHURA Biosciences, Inc. (NASDAQ: HURA - Get Free Report) dropped 3.1% on Friday. The stock traded as low as $1.87 and last traded at $1.90. Approximately 939,185 shares changed hands during trading, a decline of 17% from the average daily volume of 1,127,606 shares. The stock had previously closed at $1.96. Wall Street Analyst Weigh
prnewswire.com
Feb 27
TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
TAMPA, Fla., Feb. 27, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that on February 26, 2026, it received written notice from the Nasdaq Stock Market LLC (Nasdaq) confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2) (the "Listing Rule").
